91 related articles for article (PubMed ID: 9619834)
1. mdm2-P2 transcript levels predict the functional activity of the p53 tumor suppressor in primary leukemic cells.
Bull EK; Chakrabarty S; Brodsky I; Haines DS
Oncogene; 1998 Apr; 16(17):2249-57. PubMed ID: 9619834
[TBL] [Abstract][Full Text] [Related]
2. Induction of MDM2-P2 transcripts correlates with stabilized wild-type p53 in betel- and tobacco-related human oral cancer.
Ralhan R; Sandhya A; Meera M; Bohdan W; Nootan SK
Am J Pathol; 2000 Aug; 157(2):587-96. PubMed ID: 10934161
[TBL] [Abstract][Full Text] [Related]
3. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential.
Barak Y; Gottlieb E; Juven-Gershon T; Oren M
Genes Dev; 1994 Aug; 8(15):1739-49. PubMed ID: 7958853
[TBL] [Abstract][Full Text] [Related]
4. The high levels of p53 present in adenovirus early region 1-transformed human cells do not cause up-regulation of MDM2 expression.
Grand RJ; Lecane PS; Owen D; Grant ML; Roberts S; Levine AJ; Gallimore PH
Virology; 1995 Jul; 210(2):323-34. PubMed ID: 7618270
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells.
Gudas JM; Nguyen H; Klein RC; Katayose D; Seth P; Cowan KH
Clin Cancer Res; 1995 Jan; 1(1):71-80. PubMed ID: 9815889
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene.
Zhou M; Yeager AM; Smith SD; Findley HW
Blood; 1995 Mar; 85(6):1608-14. PubMed ID: 7888679
[TBL] [Abstract][Full Text] [Related]
7. Altered expression of p53 and MDM2 proteins in hematological malignancies.
Koníková E; Kusenda J
Neoplasma; 2003; 50(1):31-40. PubMed ID: 12687276
[TBL] [Abstract][Full Text] [Related]
8. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.
Landers JE; Cassel SL; George DL
Cancer Res; 1997 Aug; 57(16):3562-8. PubMed ID: 9270029
[TBL] [Abstract][Full Text] [Related]
9. Relationships between G1 arrest and stability of the p53 and p21Cip1/Waf1 proteins following gamma-irradiation of human lymphoma cells.
Bae I; Fan S; Bhatia K; Kohn KW; Fornace AJ; O'Connor PM
Cancer Res; 1995 Jun; 55(11):2387-93. PubMed ID: 7757991
[TBL] [Abstract][Full Text] [Related]
10. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
11. Constitutive and DNA damage inducible activation of pig3 and MDM2 genes by tumor-derived p53 mutant C277Y.
Pospísilová S; Siligan C; Ban J; Jug G; Kovar H
Mol Cancer Res; 2004 May; 2(5):296-304. PubMed ID: 15192123
[TBL] [Abstract][Full Text] [Related]
12. MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis.
Kondo S; Barnett GH; Hara H; Morimura T; Takeuchi J
Oncogene; 1995 May; 10(10):2001-6. PubMed ID: 7761100
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of the MDM2 oncogene in leukemia and lymphoma.
Watanabe T; Ichikawa A; Saito H; Hotta T
Leuk Lymphoma; 1996 May; 21(5-6):391-7, color plates XVI following 5. PubMed ID: 9172803
[TBL] [Abstract][Full Text] [Related]
14. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity.
Piovesan B; Pennell N; Berinstein NL
Oncogene; 1998 Nov; 17(18):2339-50. PubMed ID: 9811465
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells.
Capoulade C; Bressac-de Paillerets B; Lefrère I; Ronsin M; Feunteun J; Tursz T; Wiels J
Oncogene; 1998 Mar; 16(12):1603-10. PubMed ID: 9569028
[TBL] [Abstract][Full Text] [Related]
16. MDM2 and p21WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease.
Sánchez-Beato M; Piris MA; Martínez-Montero JC; García JF; Villuendas R; García FJ; Orradre JL; Martínez P
J Pathol; 1996 Sep; 180(1):58-64. PubMed ID: 8943816
[TBL] [Abstract][Full Text] [Related]
17. Modulation of Mdm2 expression and p53-induced apoptosis in immortalized human ovarian granulosa cells.
Hosokawa K; Aharoni D; Dantes A; Shaulian E; Schere-Levy C; Atzmon R; Kotsuji F; Oren M; Vlodavsky I; Amsterdam A
Endocrinology; 1998 Nov; 139(11):4688-700. PubMed ID: 9794481
[TBL] [Abstract][Full Text] [Related]
18. p53 and mdm2 in mantle cell lymphoma in leukemic phase.
Solenthaler M; Matutes E; Brito-Babapulle V; Morilla R; Catovsky D
Haematologica; 2002 Nov; 87(11):1141-50. PubMed ID: 12414343
[TBL] [Abstract][Full Text] [Related]
19. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding.
Midgley CA; Lane DP
Oncogene; 1997 Sep; 15(10):1179-89. PubMed ID: 9294611
[TBL] [Abstract][Full Text] [Related]
20. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
